Browse TEAD1

Summary
SymbolTEAD1
NameTEA domain family member 1 (SV40 transcriptional enhancer factor)
Aliases TEF-1; TCF13; AA; atrophia areata, peripapillary chorioretinal degeneration; NTEF-1; TCF-13; TEAD-1; protein ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF01285 TEA/ATTS domain family
Function

Transcription factor which plays a key role in the Hippo signaling pathway, a pathway involved in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein MST1/MST2, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Acts by mediating gene expression of YAP1 and WWTR1/TAZ, thereby regulating cell proliferation, migration and epithelial mesenchymal transition (EMT) induction. Binds specifically and cooperatively to the SPH and GT-IIC 'enhansons' (5'-GTGGAATGT-3') and activates transcription in vivo in a cell-specific manner. The activation function appears to be mediated by a limiting cell-specific transcriptional intermediary factor (TIF). Involved in cardiac development. Binds to the M-CAT motif.

> Gene Ontology
 
Biological Process GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0035329 hippo signaling
GO:0061614 pri-miRNA transcription from RNA polymerase II promoter
GO:1902893 regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1902895 positive regulation of pri-miRNA transcription from RNA polymerase II promoter
Molecular Function GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04390 Hippo signaling pathway
Reactome R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1989781: PPARA activates gene expression
R-HSA-400206: Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
R-HSA-2032785: YAP1- and WWTR1 (TAZ)-stimulated gene expression
Summary
SymbolTEAD1
NameTEA domain family member 1 (SV40 transcriptional enhancer factor)
Aliases TEF-1; TCF13; AA; atrophia areata, peripapillary chorioretinal degeneration; NTEF-1; TCF-13; TEAD-1; protein ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TEAD1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTEAD1
NameTEA domain family member 1 (SV40 transcriptional enhancer factor)
Aliases TEF-1; TCF13; AA; atrophia areata, peripapillary chorioretinal degeneration; NTEF-1; TCF-13; TEAD-1; protein ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TEAD1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX STARS Score: 4.15; FDR: 0.018 Resistant to T cell-mediated killing
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTEAD1
NameTEA domain family member 1 (SV40 transcriptional enhancer factor)
Aliases TEF-1; TCF13; AA; atrophia areata, peripapillary chorioretinal degeneration; NTEF-1; TCF-13; TEAD-1; protein ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TEAD1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2470.493
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2410.892
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6070.659
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.040.902
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0250.991
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0550.983
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0910.856
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0750.971
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1510.946
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3930.75
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2960.438
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0530.541
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TEAD1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTEAD1
NameTEA domain family member 1 (SV40 transcriptional enhancer factor)
Aliases TEF-1; TCF13; AA; atrophia areata, peripapillary chorioretinal degeneration; NTEF-1; TCF-13; TEAD-1; protein ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TEAD1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTEAD1
NameTEA domain family member 1 (SV40 transcriptional enhancer factor)
Aliases TEF-1; TCF13; AA; atrophia areata, peripapillary chorioretinal degeneration; NTEF-1; TCF-13; TEAD-1; protein ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TEAD1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TEAD1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTEAD1
NameTEA domain family member 1 (SV40 transcriptional enhancer factor)
Aliases TEF-1; TCF13; AA; atrophia areata, peripapillary chorioretinal degeneration; NTEF-1; TCF-13; TEAD-1; protein ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TEAD1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTEAD1
NameTEA domain family member 1 (SV40 transcriptional enhancer factor)
Aliases TEF-1; TCF13; AA; atrophia areata, peripapillary chorioretinal degeneration; NTEF-1; TCF-13; TEAD-1; protein ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TEAD1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTEAD1
NameTEA domain family member 1 (SV40 transcriptional enhancer factor)
Aliases TEF-1; TCF13; AA; atrophia areata, peripapillary chorioretinal degeneration; NTEF-1; TCF-13; TEAD-1; protein ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TEAD1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTEAD1
NameTEA domain family member 1 (SV40 transcriptional enhancer factor)
Aliases TEF-1; TCF13; AA; atrophia areata, peripapillary chorioretinal degeneration; NTEF-1; TCF-13; TEAD-1; protein ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TEAD1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.